Program
Evero DCB
Its studies are mostly in Peripheral Arterial Disease, led by Cook Group.
Furthest: no phase, since Aug 20, 20251 company-led study, 1 open or runningNext primary completion: Sep 2028
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cook Group | 11 open or running | no phasesince Aug 20, 2025 | Aug 20, 2025 | Sep 2028NCT07144150 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2025First study: no phase study in Peripheral Vascular DiseasesFirst studyNCT07144150 · 410 planned · United States
Ahead
- Sep 2028Primary completion: no phase study in Peripheral Vascular DiseasesNCT07144150
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07144150Peripheral Vascular Diseases · United States | – | Recruiting | Sep 2028 | 410 |
How it is read
Names in the registry
- “Evero DCB”, 1 entry
Conditions, from the studies’ own filings
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.